TrialInternational journal of hematology2020

Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients.

Ken Ishiyama et al.PubMed ↗Publisher ↗

No numbers read from the abstract.